TSXV:BTI.H - Post by User
Comment by
chrispion May 07, 2022 12:37pm
216 Views
Post# 34664508
RE:RE:RE:S&P Biotech ETF now down 38% this year alone
RE:RE:RE:S&P Biotech ETF now down 38% this year alone 20-25% of the industry is trading below the value of the cash on the balance sheet. Science with a negative value. We are in the deepest and longest biotech bear market in history.
You have to look at "trading below their cash balances" in perspective. If a biotech has a $90 mkt cap and $100m in cash but is burning thru it at a rate of $70m/year that is an issue but if it is burning thru it at $20m/year then the baby is probably being thrown out with the bathwater in that scenario. As well, biotechs that are part of an index like the XBI can be indiscriminantly sold off without any company specific news to account for it simply b/c the index is being sold or shorted. XBI is medium and large biotechs and pharmas not small and micro cap biotechs that beat to the tune of their own drum and can advance, and decline, regardless of what XBI does.
Bottom line if Bioasis continues to proves up that its technology is valuable (licensable) to other pharmas the market will give it the recognition it will deserve (higher share price) and/or another biotech or pharma will scoop it up for their own purposes.
Poof, whats next in your FUD campaign? You haven't talked about WW3 yet but I assume you will ;)